Butenafine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{Ammu}}
|authorTag={{Ammu}}
|genericName=butenafine  
|genericName=butenafine
|aOrAn=a
|aOrAn=a
|drugClass=antifungal
|drugClass=antifungal
|indication=dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare)
|indication=dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare)
|adverseReactions=Contact dermatitis , Erythema , Itching , Skin irritation  
|adverseReactions=Contact dermatitis , Erythema , Itching , Skin irritation
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
Line 16: Line 16:
|fdaLIADAdult=Mentax® (butenafine HCl) Cream, 1% is indicated for the topical treatment of the dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare). Butenafine HCl cream was not studied in immunocompromised patients.
|fdaLIADAdult=Mentax® (butenafine HCl) Cream, 1% is indicated for the topical treatment of the dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare). Butenafine HCl cream was not studied in immunocompromised patients.
Patients with tinea (pityriasis) versicolor should apply Mentax® Cream, 1%, once daily for two weeks. Sufficient Mentax® Cream should be applied to cover affected areas and immediately surrounding skin of patients with tinea versicolor. If a patient shows no clinical improvement after the treatment period, the diagnosis and therapy should be reviewed.
Patients with tinea (pityriasis) versicolor should apply Mentax® Cream, 1%, once daily for two weeks. Sufficient Mentax® Cream should be applied to cover affected areas and immediately surrounding skin of patients with tinea versicolor. If a patient shows no clinical improvement after the treatment period, the diagnosis and therapy should be reviewed.
|offLabelAdultGuideSupport=
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=* Onychomycosis due to dermatophyte<ref name="pmid10357864">{{cite journal| author=Syed TA, Qureshi ZA, Ali SM, Ahmad S, Ahmad SA| title=Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. | journal=Trop Med Int Health | year= 1999 | volume= 4 | issue= 4 | pages= 284-7 | pmid=10357864 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10357864  }} </ref>
|offLabelAdultNoGuideSupport=* Onychomycosis due to dermatophyte<ref name="pmid10357864">{{cite journal| author=Syed TA, Qureshi ZA, Ali SM, Ahmad S, Ahmad SA| title=Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. | journal=Trop Med Int Health | year= 1999 | volume= 4 | issue= 4 | pages= 284-7 | pmid=10357864 | doi= | pmc= |  
url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10357864  }} </ref>
* Seborrheic dermatitis
|contraindications=* Mentax® (butenafine HCl) Cream, 1%, is contraindicated in individuals who have known or suspected sensitivity to Mentax® Cream, 1%, or any of its components.
|warnings=* Mentax® (butenafine HCl) Cream, 1%, is not for ophthalmic, oral, or intravaginal use.


|fdaLIADPed======Condition1=====
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
<!--Off-Label Use and Dosage (Pediatric)-->
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
* Developed by:
* Class of Recommendation:
* Strength of Evidence:
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
<!--Contraindications-->
|contraindications=* Condition1
<!--Warnings-->
|warnings=* Description
====Precautions====
* Description
<!--Adverse Reactions-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.



Revision as of 19:05, 12 February 2015

Butenafine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Butenafine is a antifungal that is FDA approved for the {{{indicationType}}} of dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare). Common adverse reactions include Contact dermatitis , Erythema , Itching , Skin irritation.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Mentax® (butenafine HCl) Cream, 1% is indicated for the topical treatment of the dermatologic infection, tinea (pityriasis) versicolor due to M. furfur (formerly P. orbiculare). Butenafine HCl cream was not studied in immunocompromised patients. Patients with tinea (pityriasis) versicolor should apply Mentax® Cream, 1%, once daily for two weeks. Sufficient Mentax® Cream should be applied to cover affected areas and immediately surrounding skin of patients with tinea versicolor. If a patient shows no clinical improvement after the treatment period, the diagnosis and therapy should be reviewed.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Butenafine in adult patients.

Non–Guideline-Supported Use

  • Onychomycosis due to dermatophyte[1]
  • Seborrheic dermatitis

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Butenafine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Contraindications

  • Mentax® (butenafine HCl) Cream, 1%, is contraindicated in individuals who have known or suspected sensitivity to Mentax® Cream, 1%, or any of its components.

Warnings

  • Mentax® (butenafine HCl) Cream, 1%, is not for ophthalmic, oral, or intravaginal use.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Butenafine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Butenafine in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Butenafine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Butenafine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Butenafine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Butenafine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Butenafine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Butenafine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Butenafine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Butenafine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Butenafine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Butenafine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Butenafine in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Butenafine in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Butenafine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Butenafine in the drug label.

Pharmacology

There is limited information regarding Butenafine Pharmacology in the drug label.

Mechanism of Action

Structure

File:Butenafine01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Butenafine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Butenafine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Butenafine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Butenafine in the drug label.

How Supplied

Storage

There is limited information regarding Butenafine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Butenafine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Butenafine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Butenafine in the drug label.

Precautions with Alcohol

  • Alcohol-Butenafine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Syed TA, Qureshi ZA, Ali SM, Ahmad S, Ahmad SA (1999). "Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream". Trop Med Int Health. 4 (4): 284–7. PMID 10357864.
  2. Empty citation (help)
  3. "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Butenafine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Butenafine
 |Label Name=Butenafine11.png

}}

{{#subobject:

 |Label Page=Butenafine
 |Label Name=Butenafine11.png

}}